{"id":"https://openalex.org/W2149852822","doi":"https://doi.org/10.1177/1060028014564180","title":"Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes","display_name":"Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-06","ids":{"openalex":"https://openalex.org/W2149852822","doi":"https://doi.org/10.1177/1060028014564180","mag":"2149852822","pmid":"https://pubmed.ncbi.nlm.nih.gov/25565404"},"language":"en","primary_location":{"id":"doi:10.1177/1060028014564180","doi":"https://doi.org/10.1177/1060028014564180","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1060028014564180","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2149852822"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103214803","display_name":"Angela M. Thompson","orcid":"https://orcid.org/0000-0002-3146-8664","observed_orcids":["https://orcid.org/0000-0002-3146-8664"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Angela M. Thompson","raw_affiliation_strings":["University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054620018","display_name":"Jennifer M. Trujillo","orcid":"https://orcid.org/0000-0001-7898-8029","observed_orcids":["https://orcid.org/0000-0001-7898-8029"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer M. Trujillo","raw_affiliation_strings":["University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":5.9721,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.9737368,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"49","issue":"3","first_page":"351","last_page":"359"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":1.0},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.949999988079071},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.847000002861023},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8930000066757202},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.8500000238418579},{"id":"https://openalex.org/keywords/glucagon-suppression","display_name":"glucagon suppression","score":0.9089999794960022},{"id":"https://openalex.org/keywords/gastric-emptying","display_name":"gastric emptying","score":0.8700000047683716},{"id":"https://openalex.org/keywords/satiety","display_name":"satiety","score":0.9139999747276306},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.7120000123977661},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.7730000019073486},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9800000190734863},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.7279999852180481},{"id":"https://openalex.org/keywords/insulin-lispro","display_name":"insulin lispro","score":0.6169999837875366},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.8830000162124634},{"id":"https://openalex.org/keywords/glimepiride","display_name":"glimepiride","score":0.9039999842643738},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4320000112056732}],"concepts":[{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.9805580377578735},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8905046582221985},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.8795254230499268},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8734448552131653},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.7102669477462769},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.5838664174079895},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5546461939811707},{"id":"https://openalex.org/C2779920387","wikidata":"https://www.wikidata.org/wiki/Q417317","display_name":"Insulin glargine","level":4,"score":0.5435622930526733},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.525116503238678},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.4679972529411316},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.46206316351890564},{"id":"https://openalex.org/C2776307423","wikidata":"https://www.wikidata.org/wiki/Q425027","display_name":"Glimepiride","level":4,"score":0.4588078260421753},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4579772353172302},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.4126341640949249},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.33046889305114746},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.31290900707244873},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.27764585614204407},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.058306217193603516}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077205","descriptor_name":"Pioglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/1060028014564180","doi":"https://doi.org/10.1177/1060028014564180","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1060028014564180","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:25565404","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25565404","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Annals of pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1562038277","https://openalex.org/W1968499323","https://openalex.org/W2002057113","https://openalex.org/W2024670988","https://openalex.org/W2030546890","https://openalex.org/W2043900831","https://openalex.org/W2054981500","https://openalex.org/W2059158127","https://openalex.org/W2090054860","https://openalex.org/W2090244618","https://openalex.org/W2093375074","https://openalex.org/W2104252114","https://openalex.org/W2108106161","https://openalex.org/W2109662292","https://openalex.org/W2109677274","https://openalex.org/W2128825255","https://openalex.org/W2129934471","https://openalex.org/W2152984355","https://openalex.org/W2170606300","https://openalex.org/W2172193326","https://openalex.org/W2789732774","https://openalex.org/W4242364069"],"related_works":["https://openalex.org/W2346835864","https://openalex.org/W2799426717","https://openalex.org/W2270869067","https://openalex.org/W2588900219","https://openalex.org/W2964973823","https://openalex.org/W1973286355","https://openalex.org/W2111068175","https://openalex.org/W3000036409","https://openalex.org/W2414005931","https://openalex.org/W2028388978"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"review":[2],"the":[3,10,19,43,67,192,200],"pharmacology,":[4,68],"pharmacokinetics,":[5,69],"safety,":[6,70],"and":[7,47,83,89,99,125,132,148,166,187,224,233],"efficacy":[8,72],"of":[9,21,73,104],"glucagon-like":[11],"peptide-1":[12],"receptor":[13],"agonist":[14],"(GLP-1":[15],"RA),":[16],"dulaglutide,":[17],"in":[18,92,126,154,181,199],"treatment":[20],"type":[22],"2":[23,105],"diabetes":[24],"mellitus":[25],"(T2D).":[26],"DATA":[27,59,75],"SOURCES:":[28],"A":[29],"PubMed":[30],"search":[31,44],"was":[32],"completed":[33],"to":[34,39,52,112,157,164,173,217,222,231],"identify":[35,53],"publications":[36],"from":[37],"1947":[38],"October":[40],"2014":[41],"using":[42],"terms":[45],"dulaglutide":[46],"LY2189265.":[48],"References":[49],"were":[50,62,184],"reviewed":[51],"additional":[54],"resources.":[55],"STUDY":[56],"SELECTION":[57],"AND":[58],"EXTRACTION:":[60],"Articles":[61],"included":[63],"if":[64],"they":[65],"evaluated":[66],"or":[71],"dulaglutide.":[74],"SYNTHESIS:":[76],"Dulaglutide":[77,102,119,159,190],"reduces":[78],"both":[79],"glycosylated":[80],"hemoglobin":[81],"(A1C)":[82],"weight":[84,169,219],"by":[85,162,170],"stimulating":[86],"insulin":[87,133,145],"secretion":[88],"suppressing":[90],"glucagon":[91],"a":[93,115],"glucose-dependent":[94],"manner,":[95],"delaying":[96],"gastric":[97],"emptying,":[98],"promoting":[100],"satiety.":[101],"consists":[103],"GLP-1":[106,194],"analogues":[107],"that":[108],"have":[109],"been":[110,121],"modified":[111],"make":[113],"it":[114,167,209],"long-acting,":[116],"once-weekly":[117],"agent.":[118],"has":[120,136,225],"studied":[122],"as":[123],"monotherapy":[124],"combination":[127],"with":[128,142],"metformin,":[129,144],"glimepiride,":[130],"pioglitazone,":[131],"lispro.":[134],"It":[135,151,203],"demonstrated":[137,152],"superior":[138],"A1C":[139,155,161,214],"reduction":[140,156,220],"compared":[141],"placebo,":[143],"glargine,":[146],"sitagliptin,":[147],"twice-daily":[149],"exenatide.":[150],"noninferiority":[153],"liraglutide.":[158,234],"changed":[160,168],"-0.78%":[163],"-1.51%,":[165],"-0.35":[171],"kg":[172],"-3.03":[174],"kg.":[175],"The":[176],"most":[177],"common":[178],"adverse":[179,227],"effects":[180],"clinical":[182],"studies":[183],"nausea,":[185],"vomiting,":[186],"diarrhea.":[188],"CONCLUSIONS:":[189],"is":[191,204,210],"fifth":[193],"RA":[195],"approved":[196],"for":[197],"T2D":[198],"United":[201],"States.":[202],"an":[205,226],"attractive":[206],"option":[207],"because":[208],"dosed":[211],"once-weekly,":[212],"provides":[213],"lowering":[215],"similar":[216,221,230],"liraglutide,":[218],"exenatide,":[223],"effect":[228],"profile":[229],"exenatide":[232]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2149852822","counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":8}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
